Millennium Management
CYT

Millennium Management’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Millennium Management’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-451,980
Closed -$1.37M – 6819
2023
Q4 		$1.37M Buy
+451,980
New +$1.37M ﹤0.01% 3908
2023
Q3 		– Sell
-20,494
Closed -$53.3K – 6720
2023
Q2 		$53.3K Sell
20,494
-63,282
-76% -$132K ﹤0.01% 5460
2023
Q1 		$152K Sell
83,776
-95,590
-53% -$155K ﹤0.01% 5279
2022
Q4 		$296K Buy
179,366
+60,132
+50% +$96.5K ﹤0.01% 5120
2022
Q3 		$229K Sell
119,234
-7,915
-6% -$20.6K ﹤0.01% 5561
2022
Q2 		$380K Sell
127,149
-27,938
-18% -$71.3K ﹤0.01% 5176
2022
Q1 		$585K Buy
155,087
+103,227
+199% +$588K ﹤0.01% 5010
2021
Q4 		$590K Buy
+51,860
New +$790K ﹤0.01% 4903
2021
Q3 		– Sell
-138,165
Closed -$2.96M – 7393
2021
Q2 		$2.96M Buy
+138,165
New +$2.59M ﹤0.01% 3457

Other funds holding CYT

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return

Millennium Management's CYT Position: Q1 2024 in Review

Millennium Management sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q1 2024, closing a stake of 451,980 shares — an estimated $1.37M sold.

Millennium Management first reported a position in CYT in Q2 2021 and held it in 9 quarters. The position peaked at $2.96M in Q2 2021. 4 funds tracked by Wall St. Rank hold CYT as of Q1 2024.

  • Millennium Management reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Millennium Management sold 451,980 Cyteir Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.37M.
  • Millennium Management first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2021 and held it in 9 quarters.
  • Millennium Management's Cyteir Therapeutics, Inc. Common Stock position peaked at $2.96M in Q2 2021.
  • 4 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Millennium Management's 13F filing for Q1 2024, filed 15 May 2024.